cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28455070.v1
title: Evaluating the efficacy of basiliximab versus no induction in low-immunological-risk kidney transplant recipients: a propensity score matched analysis

description: The optimal use of induction therapy in low-immunological-risk kidney transplant recipients (KTRs) remains uncertain. While Basiliximab (BSX) is widely utilized, its comparative outcomes with no induction therapy require further evaluation. This single-center retrospective cohort study included 182 low-immunological-risk KTRs who underwent transplantation between January 2022 and March 2023. Patients were assigned to either no induction (<i>n</i> = 41) or BSX induction (<i>n</i> = 141) groups. Propensity score matching (PSM) minimized selection bias and controlled for confounding factors. Primary outcomes included the incidence of first acute rejection (AR) within 12 months, while secondary outcomes encompassed graft function, infection rates, and adverse events. After 12 months, the cumulative AR incidence was comparable between groups (<i>p</i> = 0.46). The no induction group demonstrated superior renal function, with consistently higher estimated glomerular filtration rates (eGFR) at early postoperative intervals. Additionally, this group exhibited reduced infection-related hospitalizations (respiratory infections: 7.32 vs. 29.1%, <i>p</i> = 0.008) and hematological complications (thrombocytopenia: 0.00% vs. 12.8%, <i>p</i> = 0.014). Mortality and graft loss rates were similar between groups. In low-immunological-risk KTRs, no induction therapy achieves comparable AR prevention and renal function outcomes to BSX while reducing infection and hematological complications. These findings challenge the necessity of universal induction therapy in this population and support a personalized approach to immunosuppression protocols.
DOI: 10.6084/m9.figshare.28456481
title: Comparison of the patency rates of catheter placement <i>via</i> the right external jugular vein route versus the right brachiocephalic vein route in patients experiencing tunneled-cuffed catheter loss

description: The aim of this study is to compare the patency rates of catheter placement <i>via</i> cannulation of right external jugular vein (EJV) versus the right brachiocephalic (BCV) in patients experiencing tunneled-cuffed catheter (TCC) loss. We conducted a retrospective analysis of 30 patients admitted to our department due to TCC loss. Among them, 11 patients underwent catheter reinsertion <i>via</i> the right EJV, while 19 patients underwent catheter reinsertion <i>via</i> the right BCV. We collected and compared the data of these patients. In both groups of patients, there were no cases of pneumothorax, severe adjacent artery injury, or mediastinal hematoma observed. The one-year primary patency rates of the catheters in the EVJ group and the BCV group were 54.55% and 36.84%, and the primary patency rates of two years were found to be 27.27% and 21.05% respectively. There was no statistically significant difference in the patency rates at both 1 and 2 years (<i>p</i> = 0.55, <i>p</i> = 0.71). In the face of patients experiencing TCC loss, the practice of replacing dialysis catheters via the right EJV and right BCV routes emerges as a safe and efficacious alternative strategy. Notably, no difference in catheter patency rates is observed between these divergent access routes.
DOI: 10.6084/m9.figshare.28456481.v1
title: Comparison of the patency rates of catheter placement <i>via</i> the right external jugular vein route versus the right brachiocephalic vein route in patients experiencing tunneled-cuffed catheter loss

description: The aim of this study is to compare the patency rates of catheter placement <i>via</i> cannulation of right external jugular vein (EJV) versus the right brachiocephalic (BCV) in patients experiencing tunneled-cuffed catheter (TCC) loss. We conducted a retrospective analysis of 30 patients admitted to our department due to TCC loss. Among them, 11 patients underwent catheter reinsertion <i>via</i> the right EJV, while 19 patients underwent catheter reinsertion <i>via</i> the right BCV. We collected and compared the data of these patients. In both groups of patients, there were no cases of pneumothorax, severe adjacent artery injury, or mediastinal hematoma observed. The one-year primary patency rates of the catheters in the EVJ group and the BCV group were 54.55% and 36.84%, and the primary patency rates of two years were found to be 27.27% and 21.05% respectively. There was no statistically significant difference in the patency rates at both 1 and 2 years (<i>p</i> = 0.55, <i>p</i> = 0.71). In the face of patients experiencing TCC loss, the practice of replacing dialysis catheters via the right EJV and right BCV routes emerges as a safe and efficacious alternative strategy. Notably, no difference in catheter patency rates is observed between these divergent access routes.
DOI: 10.6084/m9.figshare.29039744
title: Chronic kidney Disease overall survival prediction model based on frailty index score: construction and validation using NHANES data

description: Frailty predicts poor outcomes in chronic kidney disease (CKD) patients. This study compared frailty’s predictive power with other factors and aimed to develop a model for predicting overall survival (OS) in CKD patients. The study included 3,714 CKD participants from the National Health and Nutrition Examination Survey 2005–2018. The death data were updated to December 31, 2019. Lasso-Cox regression identified significant predictors among 42 factors, resulting in a prognostic nomogram using 11 key variables. Subsequent evaluation of the nomogram involved the C-index, the Areas Under Time-dependent Receiver Operating Characteristic Curves (AUC) and calibration curves. Over a median follow-up of 5.92 years, 1,234 deaths occurred. The final predictors of OS in CKD patients included age, ethnicity, smoking status, estimated pulse wave velocity, body fat percentage, blood uric acid concentration, blood urea nitrogen concentration, and albumin concentration, neutrophil-to-lymphocyte ratio, urine albumin-to-creatinine ratio level, and frailty index (FI) score. The FI score was the strongest predictor with an HR of 76.54 (95% CI: 42.93, 136.46, <i>p</i> &lt; 0.0001). In the training set, the AUC values were 80.11% for 1-year, 79.90% for 3-year, 79.53% for 5-year, and 81.34% for 10-year follow-ups. In the internal validation set, AUC values were 78.66%, 77.78%, 77.56%, and 79.54%, respectively. The nomogram’s corrected C-index was 0.76 (95% CI: 0.75 − 0.78), and calibration curves showed satisfactory accuracy. The FI score is a significant predictor of CKD OS. The developed nomogram based on the FI score is a promising tool for predicting the OS of CKD patients.
DOI: 10.6084/m9.figshare.28201967
title: Screening potential diagnostic biomarkers for PLA2R‑associated idiopathic membranous nephropathy by WGCNA analysis and LASSO algorithm

description: Adult nephrotic syndrome is primarily caused by membranous nephropathy (MN), with idiopathic membranous nephropathy (IMN) being a prominent subtype. The onset of phospholipase A2 receptor (PLA2R1)-associated IMN is critically linked to M-type PLA2R1 exposure, yet the mechanism underlying glomerular injury remains unclear. In this study, membranous nephropathy datasets (GSE115857, GSE200828) were retrieved from GEO. Differential gene expression was analyzed using the ‘limma’ R package. WGCNA filtered PLA2R-related modules and intersected genes. LASSO regression, evaluated by ROC analysis, identified characteristic genes. Binomial logistic regression assessed their association with IMN. Validation was performed in the GSE133288 dataset. IHC and qRT-PCR detected characteristic gene expression in PLA2R-positive patients. This study identified elevated PLA2R expression in IMN patients among 117 DEGs. PPI analysis suggested enrichment in Golgi membranes, co-regulation, and glucocorticoid responsiveness, implicating the PPAR pathway by KEGG. WGCNA revealed a 440-gene brown module associated with IMN-PLA2R, with ECM1, SLC19A2, RASD1, FOSB, KDELR3, ZFP36, and ELF4 highlighted as diagnostic markers by ROC analysis. Clinical validation confirmed ECM1 upregulation increased IMN risk, while upregulation of SLC19A2, ZFP36, RASD1, and FOSB decreased it. ECM1 positively correlated with PLA2R, whereas SLC19A2, ZFP36, and FOSB negatively correlated. IHC analysis demonstrated consistent gene expression patterns in IMN tissues, with podocyte exposure to PLA2R-positive serum reducing viability and increasing apoptosis. Functional studies, prompted by RASD1 downregulation, revealed enhanced cell activity and reduced apoptosis upon RASD1 overexpression compared to the Serum + Ov-NC control. Collectively, this study identified diagnostic markers for PLA2R-related IMN, offering novel therapeutic targets for the treatment of IMN.
DOI: 10.6084/m9.figshare.28201967.v1
title: Screening potential diagnostic biomarkers for PLA2R‑associated idiopathic membranous nephropathy by WGCNA analysis and LASSO algorithm

description: Adult nephrotic syndrome is primarily caused by membranous nephropathy (MN), with idiopathic membranous nephropathy (IMN) being a prominent subtype. The onset of phospholipase A2 receptor (PLA2R1)-associated IMN is critically linked to M-type PLA2R1 exposure, yet the mechanism underlying glomerular injury remains unclear. In this study, membranous nephropathy datasets (GSE115857, GSE200828) were retrieved from GEO. Differential gene expression was analyzed using the ‘limma’ R package. WGCNA filtered PLA2R-related modules and intersected genes. LASSO regression, evaluated by ROC analysis, identified characteristic genes. Binomial logistic regression assessed their association with IMN. Validation was performed in the GSE133288 dataset. IHC and qRT-PCR detected characteristic gene expression in PLA2R-positive patients. This study identified elevated PLA2R expression in IMN patients among 117 DEGs. PPI analysis suggested enrichment in Golgi membranes, co-regulation, and glucocorticoid responsiveness, implicating the PPAR pathway by KEGG. WGCNA revealed a 440-gene brown module associated with IMN-PLA2R, with ECM1, SLC19A2, RASD1, FOSB, KDELR3, ZFP36, and ELF4 highlighted as diagnostic markers by ROC analysis. Clinical validation confirmed ECM1 upregulation increased IMN risk, while upregulation of SLC19A2, ZFP36, RASD1, and FOSB decreased it. ECM1 positively correlated with PLA2R, whereas SLC19A2, ZFP36, and FOSB negatively correlated. IHC analysis demonstrated consistent gene expression patterns in IMN tissues, with podocyte exposure to PLA2R-positive serum reducing viability and increasing apoptosis. Functional studies, prompted by RASD1 downregulation, revealed enhanced cell activity and reduced apoptosis upon RASD1 overexpression compared to the Serum + Ov-NC control. Collectively, this study identified diagnostic markers for PLA2R-related IMN, offering novel therapeutic targets for the treatment of IMN.
DOI: 10.6084/m9.figshare.28503821
title: Lactate metabolism and lactylation in kidney diseases: insights into mechanisms and therapeutic opportunities

description: The kidney is essential for lactate metabolism. Under normal conditions, the renal cortex mainly absorbs and metabolizes lactate, with minimal amounts excreted in urine. This process is part of a glucose-lactate recycling system between the cortex and medulla. In conditions such as acute kidney injury (AKI) and diabetic kidney disease (DKD), the kidney’s ability to metabolize lactate is impaired, leading to lactate accumulation and exacerbated renal dysfunction. Novel post-translational modifications, such as lactylation, are critical in kidney disease pathophysiology by modulating gene transcription, protein function, and cellular metabolism. Lactylation is involved in inflammatory responses and tumor promotion in AKI, mitochondrial dysfunction in DKD, and tumor progression in clear cell renal cell carcinoma (ccRCC). The lactate-lactylation axis is central to the Warburg effect in ccRCC, where tumor cells preferentially rely on glycolysis rather than oxidative phosphorylation. Understanding the mechanisms of lactate metabolism and lactylation in kidney diseases may offer new therapeutic strategies. This review examines the role of lactate esters, especially lactylation, in kidney diseases, with a focus on their regulatory mechanisms and potential as therapeutic targets.
DOI: 10.6084/m9.figshare.28503821.v1
title: Lactate metabolism and lactylation in kidney diseases: insights into mechanisms and therapeutic opportunities

description: The kidney is essential for lactate metabolism. Under normal conditions, the renal cortex mainly absorbs and metabolizes lactate, with minimal amounts excreted in urine. This process is part of a glucose-lactate recycling system between the cortex and medulla. In conditions such as acute kidney injury (AKI) and diabetic kidney disease (DKD), the kidney’s ability to metabolize lactate is impaired, leading to lactate accumulation and exacerbated renal dysfunction. Novel post-translational modifications, such as lactylation, are critical in kidney disease pathophysiology by modulating gene transcription, protein function, and cellular metabolism. Lactylation is involved in inflammatory responses and tumor promotion in AKI, mitochondrial dysfunction in DKD, and tumor progression in clear cell renal cell carcinoma (ccRCC). The lactate-lactylation axis is central to the Warburg effect in ccRCC, where tumor cells preferentially rely on glycolysis rather than oxidative phosphorylation. Understanding the mechanisms of lactate metabolism and lactylation in kidney diseases may offer new therapeutic strategies. This review examines the role of lactate esters, especially lactylation, in kidney diseases, with a focus on their regulatory mechanisms and potential as therapeutic targets.
DOI: 10.6084/m9.figshare.28148657
title: Corticosteroid and immunosuppressive treatment are effective for acquired pure red cell aplasia in chronic kidney disease: a case report and literature review

description: Corticosteroid and immunosuppressive treatment are effective for acquired pure red cell aplasia in chronic kidney disease: a case report and literature review
DOI: 10.6084/m9.figshare.28148657.v2
title: Corticosteroid and immunosuppressive treatment are effective for acquired pure red cell aplasia in chronic kidney disease: a case report and literature review

description: Corticosteroid and immunosuppressive treatment are effective for acquired pure red cell aplasia in chronic kidney disease: a case report and literature review
DOI: 10.6084/m9.figshare.28935799
title: Global glomerulosclerosis proportions predict nephropathy progression in IgA nephropathy: a multicenter retrospective analysis with propensity score matching

description: Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease worldwide. The role of global glomerulosclerosis (GS) in the patients with IgAN remains controversial. The study aims to evaluate the effect of GS on the kidney outcome in the patients with IgAN. Based on the median of GS proportion, patients were divided into two groups (GS1 and GS2). Thereafter, the clinical, demographic, and treatment characteristics were evaluated by propensity score matching, Kaplan-Meier survival curves, Cox regression analyses. Next, the receiver operating characteristic curve analysis, continuous net reclassification improvement and integrated discrimination improvement were constructed to assess whether the model contained GS proportion could refine risk prediction and clinical utility. In this three-center retrospective study, a total of 1,626 IgAN patients were recruited. Both in the full and matched cohort, higher GS proportions were found to be independent prognostic factors for the kidney survival <i>via</i> Kaplan-Meier analysis (<i>p</i> &lt; 0.05, <i>p</i> &lt; 0.05, respectively). Additionally, the multivariate Cox regression models identified higher proteinuria, decreased eGFR, higher score of tubular atrophy/interstitial fibrosis (T), higher GS proportions as independent prognostic factors for poor kidney outcomes, and corticosteroids therapy was a protective indicator of kidney outcomes. Lastly, the prediction model based on these prognostic factors were validated to be accurately predict the kidney outcome when including GS proportions. GS proportions are independent predictors for poor prognosis in IgAN patients.
DOI: 10.6084/m9.figshare.28935799.v1
title: Global glomerulosclerosis proportions predict nephropathy progression in IgA nephropathy: a multicenter retrospective analysis with propensity score matching

description: Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease worldwide. The role of global glomerulosclerosis (GS) in the patients with IgAN remains controversial. The study aims to evaluate the effect of GS on the kidney outcome in the patients with IgAN. Based on the median of GS proportion, patients were divided into two groups (GS1 and GS2). Thereafter, the clinical, demographic, and treatment characteristics were evaluated by propensity score matching, Kaplan-Meier survival curves, Cox regression analyses. Next, the receiver operating characteristic curve analysis, continuous net reclassification improvement and integrated discrimination improvement were constructed to assess whether the model contained GS proportion could refine risk prediction and clinical utility. In this three-center retrospective study, a total of 1,626 IgAN patients were recruited. Both in the full and matched cohort, higher GS proportions were found to be independent prognostic factors for the kidney survival <i>via</i> Kaplan-Meier analysis (<i>p</i> &lt; 0.05, <i>p</i> &lt; 0.05, respectively). Additionally, the multivariate Cox regression models identified higher proteinuria, decreased eGFR, higher score of tubular atrophy/interstitial fibrosis (T), higher GS proportions as independent prognostic factors for poor kidney outcomes, and corticosteroids therapy was a protective indicator of kidney outcomes. Lastly, the prediction model based on these prognostic factors were validated to be accurately predict the kidney outcome when including GS proportions. GS proportions are independent predictors for poor prognosis in IgAN patients.
DOI: 10.6084/m9.figshare.28148657.v1
title: Corticosteroid and immunosuppressive treatment are effective for acquired pure red cell aplasia in chronic kidney disease: a case description and literature review

description: Corticosteroid and immunosuppressive treatment are effective for acquired pure red cell aplasia in chronic kidney disease: a case description and literature review
DOI: 10.6084/m9.figshare.28504418
title: Interactive effect of sleep duration and trouble sleeping on frailty in chronic kidney disease: findings from NHANES, 2005–2018

description: Both sleep disorders and chronic kidney disease (CKD) are recognized as significant public health concerns. In the general population, sleep disorders have been shown to be associated with frailty in the elderly. This study aims to evaluate the association between sleep duration and trouble sleeping with frailty in CKD patients, as well as the potential interactive effect between these two factors. This cross-sectional study analyzed data from the National Health and Nutrition Examination Survey (NHANES) spanning 2005–2018. Sleep duration and trouble sleeping was self-reported. Frailty was assessed using a 49-item frailty index. The associations between sleep duration, trouble sleeping, and frailty were analyzed using weighted multivariate logistic regression and restricted cubic splines. Subgroup analysis was conducted to determine the consistency of the study’s conclusions across various subgroups. A total of 5,211 adult CKD patients were included in this analysis. Regression analysis results indicated that short sleep duration (OR = 1.364, 95% CI: 1.152–1.616), long sleep duration (OR = 1.648, 95% CI: 1.259–2.157), and trouble sleeping (OR = 2.572, 95% CI: 2.102–3.147) were significantly associated with an increased risk of frailty in CKD patients, with an interaction between sleep duration and trouble sleeping. Subgroup analysis revealed that the effects of trouble sleeping and sleep duration on frailty symptoms in CKD patients exhibit significant variation across age groups (<i>p</i> &lt; 0.05 for interaction), with no notable differences observed in other subgroups. RCS results demonstrated a U-shaped relationship between frailty and sleep duration, with the lowest risk of frailty at 7.12 h of sleep. Our findings indicated that both sleep duration and trouble sleeping were significantly associated with frailty in CKD patients, with a notable interaction between these two factors. Therefore, prevention and intervention strategies for frailty in CKD patients should address multiple aspects of sleep health.
DOI: 10.6084/m9.figshare.28504418.v1
title: Interactive effect of sleep duration and trouble sleeping on frailty in chronic kidney disease: findings from NHANES, 2005–2018

description: Both sleep disorders and chronic kidney disease (CKD) are recognized as significant public health concerns. In the general population, sleep disorders have been shown to be associated with frailty in the elderly. This study aims to evaluate the association between sleep duration and trouble sleeping with frailty in CKD patients, as well as the potential interactive effect between these two factors. This cross-sectional study analyzed data from the National Health and Nutrition Examination Survey (NHANES) spanning 2005–2018. Sleep duration and trouble sleeping was self-reported. Frailty was assessed using a 49-item frailty index. The associations between sleep duration, trouble sleeping, and frailty were analyzed using weighted multivariate logistic regression and restricted cubic splines. Subgroup analysis was conducted to determine the consistency of the study’s conclusions across various subgroups. A total of 5,211 adult CKD patients were included in this analysis. Regression analysis results indicated that short sleep duration (OR = 1.364, 95% CI: 1.152–1.616), long sleep duration (OR = 1.648, 95% CI: 1.259–2.157), and trouble sleeping (OR = 2.572, 95% CI: 2.102–3.147) were significantly associated with an increased risk of frailty in CKD patients, with an interaction between sleep duration and trouble sleeping. Subgroup analysis revealed that the effects of trouble sleeping and sleep duration on frailty symptoms in CKD patients exhibit significant variation across age groups (<i>p</i> &lt; 0.05 for interaction), with no notable differences observed in other subgroups. RCS results demonstrated a U-shaped relationship between frailty and sleep duration, with the lowest risk of frailty at 7.12 h of sleep. Our findings indicated that both sleep duration and trouble sleeping were significantly associated with frailty in CKD patients, with a notable interaction between these two factors. Therefore, prevention and intervention strategies for frailty in CKD patients should address multiple aspects of sleep health.